Exosomes are the small fat and protein bubbles that cells create to manage waste and transport materials. Naturally, then, the vesicles are ideal for use in drug delivery, and researchers are using exosomes to deliver antioxidants to the brain--bypassing the challenging blood-brain barrier--to treat Parkinson's disease.
Edge Therapeutics added $56 million to its latest financing round, bringing the total Series C haul to $72.5 million in support of its neurological candidates that overcome the blood-brain barrier through surgical delivery directly to the brain.
Researchers at Northwestern University have put together a nanostructure capable of shuttling a new RNA molecule across the blood-brain barrier to reach tumor cells in mice with glioblastoma multiforme, a particularly aggressive form of brain cancer.
South Korean researchers at the University of Illinois Urbana-Champaign have developed a delivery technique that uses bits of gelatin to encapsulate drugs and carry them to the brain without surgery. The method shows promise for stroke patients, extending the window during which treatment can be effective.
Columbia University scientists showed that it is possible to control the size of the blood-brain barrier opening by varying the pressure of an ultrasound beam, a discovery that could herald major breakthroughs in the treatment of neurological diseases.
Scientists at the University of California, Davis, have successfully isolated the protein that allows a meningitis-causing fungus to cross the blood-brain barrier, a breakthrough that could lead to new treatments for the condition and other brain infections.
The blood-brain barrier is the body's way of keeping harmful substances away from the brain, but it's also a daunting obstacle for drug delivery experts looking to send treatments to the organ. Now, researchers at the Mayo Clinic have developed a synthetic peptide carrier to shuttle small molecules past the barrier and into the brain.
At the American Society for Microbiology's annual meeting this week, a team of researchers from the University of California, Davis, demonstrated a study showing that silicon nanoparticles they designed could penetrate the blood-brain barrier.
AstraZeneca's MedImmune forged a new deal with Bioasis Technologies, licensing from the Vancouver, Canada, company its brain delivery platform aimed at overcoming challenges associated with the blood-brain barrier.
To deliver large proteins past the blood-brain barrier for the treatment of Alzheimer's, researchers have developed a compound that acts as a molecular "crossing guard" for drugs to safely target brain cells and clear plaques believed to cause symptoms of the disease.